Listeria monocytogenes Cancer Vaccines: Bridging Innate and Adaptive Immunity
- 20 Downloads
Purpose of Review
Immunotherapy has emerged as a promising cancer treatment; however, success in only select clinical indications underscores the need for novel approaches. Recently Listeria monocytogenes–based vaccines have been developed to drive tumor-specific T cell responses. Here, we discuss recent preclinical studies using L. monocytogenes vaccines, innate immune pathways that influence T cell priming, and new vaccine strategies in clinical trials.
Recent studies indicate that in addition to inducing antigen-specific T cell responses, L. monocytogenes vaccines remodel the TME. In addition, several innate immune pathways influence adaptive immune responses to L. monocytogenes and modulating these pathways holds promise to enhance antitumor T cell responses.
The interplay between innate and adaptive immune responses to L. monocytogenes is poorly understood. Understanding these interactions will facilitate the design of better anti-cancer vaccines and improved use of combination therapies.
KeywordsListeria monocytogenes Immunotherapy Cancer vaccines Innate immunity Adaptive immunity Tumor microenvironment
This study was supported by grant R01 CA188034 from the National Institutes of Health (JDS). In addition, this material is based upon work supported by the National Science Foundation Graduate Research Fellowship Program (Z.T.M) under Grant No. DGE-1747503. Support was also provided by the Graduate School and the Office of the Vice Chancellor for Research and Graduate Education at the University of Wisconsin-Madison with funding from the Wisconsin Alumni Research Foundation.
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Any opinions, findings, and conclusions or recommendations expressed in this material are those of the author(s) and do not necessarily reflect the views of the National Science Foundation.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 28.Brocksted DG, Giedlin MA, Leong ML, Bahjat KS, Gao Y, Luckett W, et al. Listeria-based cancer vaccines that segregate immunogenicity from toxicity. Proc Natl Acad Sci U S A. 2004;101:13832–7.Google Scholar
- 32.Gunn GR, Zubair A, Peters C, Pan Z-KZ-K WT-CT-C, Paterson Y. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortal. J Immunol. 2001;167:6471–9.PubMedCrossRefPubMedCentralGoogle Scholar
- 35.Souders NC, Sewell DA, Pan ZK, Hussain SF, Rodriguez A, Wallecha A, et al. Listeria-based vaccines can overcome tolerance by expanding low avidity CD8+ T cells capable of eradicating a solid tumor in a transgenic mouse model of cancer. Cancer Immun. 2007;7:2.Google Scholar
- 40.•• Deng W, Lira V, Hudson TE, et al. Recombinant Listeria promotes tumor rejection by CD8 + T cell-dependent remodeling of the tumor microenvironment. Proc Natl Acad Sci U S A. 2018;115:8179–84 This study describes mechanisms of howL. monocytogenesvaccines modify the tumor microenvironment in both antigen-specific and non-specific ways. Importantly, the group shows thatL. monocytogenesvaccines are particularly effective in comparison with other therapeutic modalities in part, due to the effects on the TME. PubMedPubMedCentralCrossRefGoogle Scholar
- 41.Shrimali R, Ahmad S, Berrong Z, Okoev G, Matevosyan A, Razavi GSE, et al. Agonist anti-GITR antibody significantly enhances the therapeutic efficacy of Listeria monocytogenes-based immunotherapy. J Immunother Cancer. 2017;5:1–9. https://doi.org/10.1186/s40425-017-0266-x.
- 43.Olino K, Wada S, Edil BH, Pan X, Meckel K, Weber W, et al. Tumor-associated antigen expressing listeria monocytogenes induces effective primary and memory T-cell responses against hepatic colorectal cancer metastases. Ann Surg Oncol. 2012;19:597–607. https://doi.org/10.1245/s10434-011-2037-0.PubMedCentralCrossRefGoogle Scholar
- 51.Johnson LE, Brockstedt D, Leong M, Lauer P, Theisen E, Sauer JD, et al. Heterologous vaccination targeting prostatic acid phosphatase (PAP) using DNA and Listeria vaccines elicits superior anti-tumor immunity dependent on CD4+ T cells elicited by DNA priming. Oncoimmunology. 2018;7:e1456603.Google Scholar
- 57.Le DT, Ko AH, Wainberg ZA, et al. Results from a phase 2b, randomized, multicenter study of GVAX pancreas and CRS-207 compared to chemotherapy in adults with previously-treated metastatic pancreatic adenocarcinoma (ECLIPSE Study). J Clin Oncol. 2017;35:345–5.Google Scholar
- 62.Witte CE, Archer KA, Rae CS, Sauer JD, Woodward JJ, Portnoy DA. Innate immune pathways triggered by listeria monocytogenes and their role in the induction of cell-mediated immunity. Adv Immunol. 2012:135–56.Google Scholar
- 67.• Archer KA, Durack J, Portnoy DA. STING-dependent type I IFN production inhibits cell-mediated immunity to Listeria monocytogenes. PLoS Pathog. 2014;10:1003861 This study examines how STING-dependent type I interferon negatively impacts the generation of antigen-specific T cell responses toL. monocytogenesinfection. CrossRefGoogle Scholar
- 71.Sauer JD, Sotelo-Troha K, von Moltke J, Monroe KM, Rae CS, Brubaker SW, et al. The N-ethyl-N-nitrosourea-induced Goldenticket mouse mutant reveals an essential function of Sting in the in vivo interferon response to Listeria monocytogenes and cyclic dinucleotides. Infect Immun. 2011;79:688–94.Google Scholar
- 79.• Sivick KE, Desbien AL, Glickman LH, et al. Magnitude of therapeutic STING activation determines CD8 + T cell-mediated anti-tumor immunity. Cell Rep. 2018;25:3074–85 This study demonstrates that the magnitude and location (i.e., systemic vs local) of STING-activation are critical for shaping T cell responses in tumors. PubMedCrossRefGoogle Scholar
- 87.Franchi L, Park JH, Shaw MH, Marina-Garcia N, Chen G, Kim YG, et al. Intracellular NOD-like receptors in innate immunity, infection and disease. Cell Microbiol. 2008;10:1–8.Google Scholar
- 91.•• Theisen E, Sauer JD. Listeria monocytogenes-induced cell death inhibits the generation of cell-mediated immunity. Infect Immunol. 2017;85:e00733–16 This study examines the mechanism of how inflammasome activation impairs the generation of antigen-specific T cell responses duringL. monocytogenesinfection. Importantly, the authors demonstrate that rather than pyroptotic death of APCs, it is the inflammation associated with inflammasome activation that impairs adaptive immunity. CrossRefGoogle Scholar
- 96.Huang CF, Chen L, Li YC, Wu L, Yu GT, Zhang WF, et al. NLRP3 inflammasome activation promotes inflammation-induced carcinogenesis in head and neck squamous cell carcinoma. J Exp Clin Cancer Res. 2017;36:116.Google Scholar
- 104.Liu ZY, Yi J, Liu FE. The molecular mechanism of breast cancer cell apoptosis induction by absent in melanoma (AIM2). Int J Clin Exp Med. 2015;8:14750–8.Google Scholar
- 106.Liu R, Truax AD, Chen L, Hu P, Li Z, Chen J, et al. Expression profile of innate immune receptors, NLRs and AIM2, in human colorectal cancer: correlation with cancer stages and inflammasome components. Oncotarget. 2015;6:33456–69.Google Scholar
- 109.Sibelius U, Rose F, Chakraborty T, Darji A, Wehland J, Weiss S, et al. Listeriolysin is a potent inducer of the phosphatidylinositol response and lipid mediator generation in human endothelial cells. Infect Immun. 1996;64:674–6.Google Scholar
- 113.• Theisen E, McDougal CE, Nakanishi M, Stevenson DM, Amador-Noguez D, Rosenberg DW, et al. Cyclooxygenase-1 and -2 play contrasting roles in Listeria-stimulated immunity. J Immunol. 2018;200:3729–38 This study demonstrates that eicosanoids are produced duringL. monocytogenesinfection and influence T cell priming. Importantly, the authors show that the critical eicosanoid mediating the generation of antigen-specific T cell responses is PGE 2. PubMedCrossRefGoogle Scholar
- 127.Mason NJ, Gnanandarajah JS, Engiles JB, Gray F, Laughlin D, Gaurnier-Hausser A, et al. Immunotherapy with a HER2-targeting listeria induces HER2-specific immunity and demonstrates potential therapeutic effects in a phase I trial in canine osteosarcoma. Clin Cancer Res. 2016;22:4380–90.PubMedCrossRefGoogle Scholar